Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable Hepacellular Carcinoma

NCT03053596 is registered in ClinicalTrials.gov with Terumo Europe N.V. as lead sponsor.

NCT NCT03053596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03053596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable Hepacellular Carcinoma
Lead sponsor
Terumo Europe N.V.
Phase
Observational
Overall status
Completed
Start date
November 30, 2016
Completion date
October 8, 2019
Enrollment
102 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma